Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Testing, testing, one, two, hearing music on the KV preview. Here is the audio from Zoom. And just waiting for it to kick in. Should be streaming by tomorrow morning, I think. Sorry, just always amazes me how long the delay is for KV. Hello, hello. Oh, there we go. Let's see. Music stopped. There we go. Sweet. Perfect. Good enough, Micah. Thanks, man. and before tomorrow morning even. Thank you. Thank you for watching. so so Thank you. Thank you. you Thank you. Thank you for watching. you Thank you. You are the light of my life. You are the light of my life. so so Thank you. Thank you. Thank you. Thank you. Thank you. ¦ ¦ Thank you. ¦ ¦ ¦ ¦ Thank you. ¦ ¦ ¦ Thank you. Thank you. ¦ ¦ Thank you. ¦ ¦ Thank you. Thank you. Thank you. ¶¶ ¶¶ ¦ ¦ Good day, everyone, and welcome to the Syndax third quarter 2025 earnings conference call. Today's call is being recorded. If you would like to ask a question following the company's prepared remarks, please press star five during the call. At this time, I would like to turn the call over to Sharon Clary, head of investor relations at Syndax Pharmaceuticals. Thank you, Operator. Thank you, Operator. Welcome and thank you all for joining us today for a review of Syndax's third quarter 2025 financial and operating results. I'm Sharon Clary. With me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer, Steve Kloster, Chief Commercial Officer, Dr. Nitba Wood, Head of R&D and Chief Medical Officer, and Keith Goldan, Chief Financial Officer. Also joining us on the call today for the question and answer session are Dr. Peter O'Dentlick, Chief Scientific Officer, and Dr. Anjali Ganguly, Chief Strategy Officer. Thank you very much. Actual results may differ ...